Discounted Cash Flow
Lifecore Biomedical, Inc. \de\
—
—
Average annual growth rates
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
| Dividends | — | — | — |
Endpoint CAGR (better for long term trend)
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Projected growth rate
—
—
%
%
Historical inputs (10 fiscal years)
| YEAR | Sales | Net Income | Free Cash Flow | Net Margin | EPS (diluted) |
|---|---|---|---|---|---|
| 2016 | $541.1m | $-11.6m | $-19.1m | -2.2% | $-0.43 |
| 2017 | $532.3m (-1.6%) | $10.6m (191.0%) | $6.7m (135.3%) | 2.0% (192.5%) | $0.39 (190.7%) |
| 2018 | $524.2m (-1.5%) | $24.8m (134.5%) | $-13.8m (-305.1%) | 4.7% (138.0%) | $0.90 (130.8%) |
| 2019 | $557.6m (6.4%) | $411.0k (-98.3%) | $-28.7m (-107.9%) | 0.1% (-98.4%) | $0.01 (-98.9%) |
| 2020 | $590.4m (5.9%) | $-38.2m (-9392.2%) | $-43.7m (-52.3%) | -6.5% (-8875.8%) | $-1.31 (-13200.0%) |
| 2021 | $544.2m (-7.8%) | $-32.7m (14.5%) | $-8.8m (80.0%) | -6.0% (7.2%) | $-1.12 (14.5%) |
| 2022 | $185.8m (-65.9%) | $-114.7m (-251.1%) | $-50.6m (-478.4%) | -61.7% (-928.3%) | $-3.90 (-248.2%) |
| 2023 | $103.3m (-44.4%) | $-99.6m (13.2%) | $-24.4m (51.8%) | -96.4% (-56.2%) | $-3.32 (14.9%) |
| 2024 | $128.3m (24.2%) | $12.0m (112.1%) | $-18.6m (23.7%) | 9.4% (109.7%) | $0.40 (112.0%) |
| 2025 | $128.9m (0.5%) | $-38.7m (-422.3%) | $-13.6m (26.8%) | -30.0% (-420.8%) | $-1.27 (-417.5%) |
Base FCF: — (latest fiscal year)
Discount rate: % —
Terminal growth: —
Projection period: — years
Alt A decline yrs:
Alt B total yrs:
Projected cash flows
| Year | Projected cash flow | Discount Factor | Present Value |
|---|
PV of projected FCF: —
Terminal FCF: —
Terminal value: —
PV of terminal value: —
Enterprise value (DCF): —
Current price: —
—Alternative DCF Models
| Model | Fair Value | Upside | PV(FCFs) | PV(Terminal) | Total Years |
|---|---|---|---|---|---|
| Standard (10yr→TV) | — | — | — | — | 10 + TV |
| Alt A (Gradual Decline) | — | — | — | — | — |
| Alt B (30yr Hard Stop) | — | — | — | N/A | — |
This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.